MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Trial Identifier: D6070C00005
Sponsor: MedImmune, LLC
NCTID:: NCT03611556
Start Date: June 2018
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (Australian) Translations
Spanish Translations
Norwegian Translations

Trial Locations

Country Location
AU Blacktown, AU, 2148
AU Clayton, AU, 3168
AU Heidelberg, AU, 3084
AU St Leonards, AU, 2065
ES Barcelona, ES, 08035
ES Fuenlabrada, ES, 28942
ES Oviedo, ES, 33011
ES Pamplona, ES, 31008
NO Oslo, NO, N-0379
US, CA La Jolla, CA, US, 92093
US, CO Aurora, CO, US, 80045
US, FL Ft Myers, FL, US, 33901
US, GA Atlanta, GA, US, 30322
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MI Ann Arbor, MI, US, 48109
US, NC Durham, NC, US, 27710
US, NY Buffalo, NY, US, 14263
US, OH Cincinnati, OH, US, 45219
US, OH Columbus, OH, US, 43210
US, PA Philadelphia, PA, US, 19111
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75235
US, TX Houston, TX, US, 77030
US, VA Charlottesville, VA, US, 22908
US, WA Seattle, WA, US, 98109
US, WI Madison, WI, US, 53705